Page 1
Experts from Immunize.org answer your questions about hepatitis B (HepB) vaccine. You’ll find additional Q&As about hepatitis B vaccine on the “Ask the Experts” section of immunize.org at www.immunize.org/askexperts/experts_ hepb.asp Hepatitis B Vaccination Which people who work in healthcare settings need hepatitis B vaccine? CDC recommends hepatitis B vaccination of everyone age 59 years and younger plus people 60 years and older who are at increased risk, including all healthcare personnel (HCP). In addition, the Occupational Safety and Health Administration (OSHA) requires that hepatitis B vaccine be offered to HCP who have a reasonable expectation of being exposed to blood or body fluids on the job. This requirement does not include personnel who would not be expected to have occupational risk (e.g., general office workers). At what anatomic site should hepatitis B vaccine be administered to adults? What needle size should be used? For adults, administer hepatitis B vaccine intramuscularly (IM) in the deltoid muscle. A 22- to 25-gauge, 1–1½ inch needle should be used. The gluteus muscle should not be used as a site for administering hepatitis B vaccine. For optimal protection, it is crucial that the vaccine be administered IM, not subcutaneously. How is Heplisav-B different from the 3-dose HepB vaccines? Heplisav-B (Dynavax) was approved by the Food and Drug Administration in November 2017 for persons 18 years of age and older. Heplisav-B contains a novel immunostimulatory adjuvant (CpG 1018) that binds to Toll-like receptor 9 to stimulate a directed immune response to HBsAg. It is provided in a single dose 0.5 mL vial and given as a 2-dose schedule. The doses should be separated by at least 4 weeks. Can you complete hepatitis B vaccination using different brands of HepB? A HepB vaccine series that was begun with one brand of hepatitis B vaccine may be completed with a different brand. When feasible, the same manufacturer’s vaccines should be used to complete the series. However, vaccination should not be deferred when the manufacturer of the previously administered vaccine is unknown or when the vaccine from the same manufacturer is unavailable. The 2-dose hepatitis B vaccine series only applies when both doses in the series consist of Heplisav-B. Series consisting of a combina- tion of 1 dose of Heplisav-B and a vaccine from a different manufacturer should consist of 3 total vaccine doses and should adhere to the 3-dose schedule minimum intervals of 4 weeks between dose 1 and 2, 8 weeks between dose 2 and 3, and 16 weeks between dose 1 and 3. Doses administered at less than the minimum interval should be repeated. However, a series containing 2 doses of Heplisav-B administered at least 4 weeks apart is valid, even if the patient received a single earlier dose from another manufacturer. If a person who works in a healthcare setting had one dose only of hepatitis B vaccine 5 years ago, should the series be restarted? No. The hepatitis B vaccine series should not be restarted when doses are delayed; rather, the series should be continued from where it stopped. Is it safe for HCP to be vaccinated during pregnancy? Yes. Engerix-B [GSK], Recombivax HB [Merck]), or Heplisav-B (Dynavax) may be administered during pregnancy. Current hepatitis B vaccines contain noninfectious hepatitis B surface antigen (HBsAg) and pose no risk to the fetus. HCP who breastfeed their babies can and should be vaccinated against hepatitis B if they haven’t been previously vaccinated. Receipt of the vaccine is not a reason to discontinue breast-feeding. Is there a recommendation for routine booster doses of hepatitis B vaccine? No. HCP who have documentation of receiving a complete series of hepatitis B vaccine and who subsequently tested positive for anti-HBs (defined as anti-HBs of ≥10 mIU/mL) are considered to be immune to hepatitis B. Immunocompetent people have long-term protection against HBV and do not need further testing or vaccine doses. Some immunodeficient persons, including those on hemodialysis, may need periodic booster doses of hepatitis B vaccine. We have a new employee with documentation of having received a series of hepatitis B vaccine as an adolescent. He now tests negative for hepatitis B surface antibody (anti-HBs). How should we manage him? ACIP recommends that HCP with written documentation of having received a properly spaced series of hepatitis B vaccine in the past (such as in infancy or adolescence) but who now test negative for anti-HBs should receive a single challenge dose of hepatitis B vaccine and be retested for anti-HBs 1–2 months later (see Figure 1). Those who test positive following the challenge dose are immune and require no further vaccination or testing. Those who test negative should complete a second series of hepatitis B vaccine on the usual schedule and be tested again 1–2 months after the last dose. Heplisav-B may be used to revaccinate new HCP (including the challenge dose) initially vaccinated with a vaccine from a different manufacturer in the past who have anti-HBs less than 10 mIU/mL upon hire or matriculation. For more information, see www.cdc.gov/ mmwr/volumes/67/rr/pdfs/rr6701-H.PDF, pages 21–22. Post-vaccination Anti-HBs Testing Which HCP need serologic testing after receiving a hepatitis B vaccine series? All HCP, including trainees, who have a high risk of occupational percutaneous or mucosal exposure to blood or body fluids (for example, HCP with direct patient contact, HCP at risk of needlestick or sharps injury, laboratory workers who draw, test or handle blood specimens) should have postvaccination testing for antibody to hepatitis B surface antigen (anti-HBs). Postvaccination testing Hepatitis B and Healthcare Personnel Immunize.org answers frequently asked questions about how to protect healthcare personnel FOR PROFESSIONALS www.immunize.org / FOR THE PUBLIC www.vaccineinformation.org www.immunize.org/catg.d/p2109.pdf Item #P2109 (1/23/2025) Scan for PDF continued on the next page
